Mesa Laboratories, Inc. (MLAB) Given Consensus Rating of “Strong Buy” by Analysts

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus price target of $175.00 for the company and are expecting that the company will post $0.61 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 168 out of 265 based on the ratings given to its competitors.

Several research firms have recently weighed in on MLAB. BidaskClub lowered Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. TheStreet lowered Mesa Laboratories from a “b” rating to a “c+” rating in a research report on Monday, July 31st. Finally, Zacks Investment Research lowered Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research report on Friday, November 10th.

ILLEGAL ACTIVITY WARNING: “Mesa Laboratories, Inc. (MLAB) Given Consensus Rating of “Strong Buy” by Analysts” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2017/11/19/mesa-laboratories-inc-mlab-given-consensus-rating-of-strong-buy-by-analysts.html.

In related news, Director H Stuart Campbell sold 1,000 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $130.16, for a total value of $130,160.00. Following the completion of the sale, the director now directly owns 42,366 shares of the company’s stock, valued at approximately $5,514,358.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.70% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its position in Mesa Laboratories by 2.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,117 shares of the medical instruments supplier’s stock valued at $446,000 after buying an additional 71 shares in the last quarter. Strs Ohio boosted its stake in Mesa Laboratories by 5.6% during the 2nd quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock valued at $272,000 after purchasing an additional 100 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Mesa Laboratories by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,564 shares of the medical instruments supplier’s stock valued at $367,000 after purchasing an additional 169 shares during the last quarter. Swiss National Bank boosted its stake in Mesa Laboratories by 9.6% during the 2nd quarter. Swiss National Bank now owns 5,702 shares of the medical instruments supplier’s stock valued at $817,000 after purchasing an additional 500 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Mesa Laboratories by 19.9% during the 2nd quarter. Wells Fargo & Company MN now owns 3,326 shares of the medical instruments supplier’s stock valued at $476,000 after purchasing an additional 553 shares during the last quarter. 68.53% of the stock is owned by institutional investors and hedge funds.

Shares of Mesa Laboratories (NASDAQ MLAB) traded up $1.01 on Friday, reaching $133.40. The company’s stock had a trading volume of 28,217 shares, compared to its average volume of 21,442. The firm has a market cap of $504.22, a P/E ratio of 35.29 and a beta of 0.49. Mesa Laboratories has a 52-week low of $113.57 and a 52-week high of $169.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.86 and a quick ratio of 1.97.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.64 by ($0.04). Mesa Laboratories had a return on equity of 14.77% and a net margin of 11.48%. The company had revenue of $22.95 million for the quarter, compared to analyst estimates of $25.50 million. equities research analysts forecast that Mesa Laboratories will post 2.47 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Thursday, November 30th will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.48%. The ex-dividend date of this dividend is Wednesday, November 29th. Mesa Laboratories’s dividend payout ratio (DPR) is presently 23.10%.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply